Daphne Karydas's Insider Trades & SAST Disclosures

Daphne Karydas's most recent trade in Mineralys Therapeutics Inc was a trade of 32,900 Stock Option done . Disclosure was reported to the exchange on Feb. 13, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Mineralys Therapeutics Inc
Daphne Karydas Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 32,900 32,900 - - Stock Option
Mineralys Therapeutics Inc
Daphne Karydas Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 May 2024 22,000 22,000 - - Stock Option
Compass Pathways Plc - ADR
Daphne Karydas Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 May 2024 26,000 26,000 - - Share Option (Right to Buy)
Syndax Pharmaceuticals Inc
Daphne Karydas Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2021 95,000 95,000 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades